XML 44 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration Agreements (Bayer) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Mar. 31, 2017
Collaboration Agreement [Line Items]      
Accounts receivable from Bayer $ 243,141 $ 242,014  
Other Collaboration Revenue 247,928   $ 193,939
EYLEA      
Collaboration Agreement [Line Items]      
Net profit (loss) from commercialization of products under collaboration agreement 232,068   174,876
Reimbursement of Regeneron research and development expenses 3,457   2,451
Contracts Revenue 11,863   10,603
Other Collaboration Revenue 247,388   $ 187,930
Ang2 Antibody [Member]      
Collaboration Agreement [Line Items]      
Up-front payment received   50,000  
EYLEA      
Collaboration Agreement [Line Items]      
Accounts receivable from Bayer 243,141 241,153  
Deferred Revenue 70,378 $ 68,734  
Bayer HealthCare LLC [Member]      
Collaboration Agreement [Line Items]      
Deferred Revenue, Period Increase (Decrease) 11,436    
Deferred Revenue, Revenue Recognized $ (9,792)    
Minimum [Member] | EYLEA      
Collaboration Agreement [Line Items]      
Revenue based on percentage of annual sales in Japan 33.50%    
Maximum [Member] | EYLEA      
Collaboration Agreement [Line Items]      
Revenue based on percentage of annual sales in Japan 40.00%